ESPAC-4: Adjuvant Gemcitabine/Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma

June 3-7, 2016; Chicago, Illinois
Survival benefit was consistent across prognostic criteria of grade, disease stage, lymph node involvement, and resection margins, and there was no significant difference in treatment-related serious adverse events between the 2 treatment arms.
Format: Microsoft PowerPoint (.ppt)
File Size: 678 KB
Released: June 14, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

From Clinical Care Options (CCO), download a PDF featuring key points from an expert discussion on PARP inhibitors in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: November 3, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue